The content on this site is intended for healthcare professionals only
Dr Davies speaks with ecancertv at ASH 2016 about phase III trials of obinutuzumab, an anti-CD20 monoclonal antibody for the treatment of follicular lymphoma.
He describes the influence of pre-treatment on tolerability, and draws comparison to rituximab based chemotherapy for efficacy, but notes concerns over toxicity management.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
OncoAlert Round Up for August 25th - 31st, 2023
Choosing Wisely in radiology Tanzania
